Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma
- PMID: 20444731
- DOI: 10.1177/1066896910364229
Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma
Abstract
The fibrolamellar variant of hepatocellular carcinoma (FLC) differs from conventional hepatocellular carcinoma (HCC) in some clinical and pathological features. The authors investigated possible differences in reactivity between FLCs and HCCs using glypican-3 (GPC3), an oncofetal protein, and survivin, an antiapoptotic protein. They also compared staining of FLC and HCC with antibodies to cytokeratins 7 (CK7) and 19 (CK19) and CD34. GPC3 was significantly more often and more strongly expressed in HCCs (72%) than in FLCs (17%). Survivin nuclear translocation in tumor cells did not differ between HCCs (10%) and FLCs (9%). There was more abundant expression of CK7 in FLCs (92%) than in HCCs (33%), whereas CK19 was more often found in HCCs (20%) than in FLCs (5%). All tumors had CD34-positive sinusoids. This study shows that FLCs and HCCs differ in the expression of GPC3, CK7, and CK19 and that there is a lack of difference as regards survivin and CD34.
Similar articles
-
Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.J Clin Pathol. 2013 Aug;66(8):687-91. doi: 10.1136/jclinpath-2012-201156. Epub 2013 Apr 12. J Clin Pathol. 2013. PMID: 23585667
-
Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases.Hepatogastroenterology. 2005 Mar-Apr;52(62):519-23. Hepatogastroenterology. 2005. PMID: 15816470
-
Primary liver carcinoma arising in people younger than 30 years.Am J Clin Pathol. 2005 Oct;124(4):512-8. doi: 10.1309/TT0R7KAL32228E99. Am J Clin Pathol. 2005. PMID: 16146811
-
Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.Adv Anat Pathol. 2009 Mar;16(2):125-9. doi: 10.1097/PAP.0b013e3181992455. Adv Anat Pathol. 2009. PMID: 19550373 Review.
-
Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.FEBS J. 2013 May;280(10):2471-6. doi: 10.1111/febs.12126. Epub 2013 Jan 31. FEBS J. 2013. PMID: 23305321 Review.
Cited by
-
CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.Gastroenterology. 2017 Dec;153(6):1662-1673.e10. doi: 10.1053/j.gastro.2017.09.008. Epub 2017 Sep 18. Gastroenterology. 2017. PMID: 28923495 Free PMC article.
-
New insights into the pathophysiology and clinical care of rare primary liver cancers.JHEP Rep. 2020 Aug 24;3(1):100174. doi: 10.1016/j.jhepr.2020.100174. eCollection 2021 Feb. JHEP Rep. 2020. PMID: 33205035 Free PMC article. Review.
-
Fibrolamellar carcinoma: 2012 update.Scientifica (Cairo). 2012;2012:743790. doi: 10.6064/2012/743790. Epub 2012 Sep 23. Scientifica (Cairo). 2012. PMID: 24278737 Free PMC article. Review.
-
mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma.Mod Pathol. 2015 Jan;28(1):103-10. doi: 10.1038/modpathol.2014.78. Epub 2014 Jun 13. Mod Pathol. 2015. PMID: 24925055
-
Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.Int J Mol Sci. 2021 May 28;22(11):5780. doi: 10.3390/ijms22115780. Int J Mol Sci. 2021. PMID: 34071338 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials